Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Cases Having a Gleason Score 3+4=7 With <5% of Gleason Pattern 4 in Prostate Needle Biopsy Show Similar Failure-free Survival and Adverse Pathology Prevalence to Gleason Score 6 Cases in a Radical Prostatectomy Cohort

Sato, Shun MD*; Kimura, Takahiro MD, PhD; Yorozu, Takashi MD*; Onuma, Hajime MD; Iwatani, Kosuke MD; Egawa, Shin MD, PhD; Ikegami, Masahiro MD, PhD*; Takahashi, Hiroyuki MD, PhD*

The American Journal of Surgical Pathology: November 2019 - Volume 43 - Issue 11 - p 1560–1565
doi: 10.1097/PAS.0000000000001345
Original Articles

Recent discussions have suggested expanding the inclusion criteria for active prostate cancer surveillance to include cases with a Gleason score (GS) of 3+4=7. In this study, we examined this proposed use of a limited percent Gleason pattern 4 (%GP4) to identify candidates of active surveillance among 315 patients who underwent radical prostatectomy for prostate cancer with a GS of 6 or 3+4=7 via needle biopsy. The latter cases were divided into 4 groups using highest or overall %GP4 cut-off values of 5% and 10% as determined from prostate needle biopsies. The frequency of adverse pathology and risk of biochemical recurrence were compared between the GS 6 and both GS 3+4=7 groups. Adverse pathology was defined as a GS 4+3=7 or higher, pT3b staging or positive lymph node metastasis. Notably, the Gleason pattern 4 <5% and GS 6 groups did not differ significantly in terms of the frequency of adverse pathology and risk of biochemical recurrence by the highest method. However, other highest Gleason pattern 4 categories had significantly higher frequencies and risks. Using the overall method, even the Gleason pattern 4 <5% group had a significantly higher frequency of adverse pathology and risk of biochemical recurrence relative to the GS 6 group. In conclusion, our findings suggest that patients with a GS 3+4=7 on biopsy with a highest %GP4 <5% are similar candidates for active surveillance to men with GS 6 cancers.

Departments of *Pathology

Urology, The Jikei University School of Medicine, Tokyo, Japan

Conflicts of Interest and Source of Funding: The authors have disclosed that they have no significant relationships with, or financial interest in, any commercial companies pertaining to this article.

Correspondence: Hiroyuki Takahashi, MD, PhD, Department of Pathology, The Jikei University School of Medicine, 3-25-8 Nishishimbashi, Minato-ku, Tokyo 105-8461, Japan (e-mail:

Online date: August 20, 2019

Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.